While WEE1 inhibition as monotherapy appears to only have modest effects in AML cell lines, the WEE1 inhibitor AZD1775 (AstraZeneca) shows evidence of synergy with the PARP inhibitor olaparib (AstraZeneca) in primary AML samples as well as murine models (100), suggesting possibilities for DDRi combination trials in AML. Here, PARP1 is linked to acute myeloid leukemia.